<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1689">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03613844</url>
  </required_header>
  <id_info>
    <org_study_id>HS-18-00291/00984</org_study_id>
    <secondary_id>R01AG054434</secondary_id>
    <secondary_id>GC-201711-2014197</secondary_id>
    <nct_id>NCT03613844</nct_id>
  </id_info>
  <brief_title>DHA Brain Delivery Trial</brief_title>
  <acronym>PreventE4</acronym>
  <official_title>The Delivery of Essential Fatty Acids to the Brain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Huntington Medical Research Institutes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alzheimer's Drug Discovery Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Carrying the APOE ɛ4 allele is the strongest genetic risk factor for developing Alzheimer's&#xD;
      disease. The goal of this project is to identify whether carrying the APOE ɛ4 allele is&#xD;
      associated with reduced delivery of DHA to the brain. This information will help us identify&#xD;
      the target population that could benefit from DHA supplementation to prevent cognitive&#xD;
      decline.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Brain DHA Delivery Trial will examine the effect of APOE genotype on the changes of&#xD;
      cerebrospinal fluid (CSF) DHA to Arachidonic acid (AA) ratio in 184 cognitively healthy older&#xD;
      individuals in response to DHA supplementation. Randomized clinical trials have yielded mixed&#xD;
      results on the effect DHA supplementation on cognitive outcomes. This study asks the critical&#xD;
      question of whether DHA gets into the brain in sufficient amounts after supplementation, and&#xD;
      whether APOE genotype affects brain penetrance.&#xD;
&#xD;
      This trial will also test the effect of DHA supplementation on changes in brain structural&#xD;
      and functional connectivity assessed by MRI, and changes in cognition after two years of&#xD;
      supplementation in all 368 participants.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">May 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>double blind and randomized placebo controlled</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in cerebrospinal fluid fatty acid levels after the intervention in 184 subjects</measure>
    <time_frame>6 months</time_frame>
    <description>cerebrospinal fluid fatty acids assessed by mass spectrometry</description>
  </primary_outcome>
  <other_outcome>
    <measure>Change in functional connectivity using resting state functional MRI in all 368 participants</measure>
    <time_frame>2 years</time_frame>
    <description>Functional Connectivity</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in structural connectivity using MRI in all 368 participants</measure>
    <time_frame>2 years</time_frame>
    <description>Structural connectivity</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in cognitive measures using the Neuropsychological Outcomes (RBANS) in all 368 participants</measure>
    <time_frame>2 years</time_frame>
    <description>RBANS battery</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Brain DHA Delivery and Alzheimer's Disease Risk</condition>
  <arm_group>
    <arm_group_label>DHA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral DHA supplementation at 2 grams per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for DHA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DHA</intervention_name>
    <description>DHA supplementation</description>
    <arm_group_label>DHA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for DHA</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: ≥ 55 and ≤ 80&#xD;
&#xD;
          -  At least one dementia risk factor (obesity, education years, hypertension,&#xD;
             hyperlipidemia)&#xD;
&#xD;
          -  Mini-Mental State Examination (MMSE) ≥ 25&#xD;
&#xD;
          -  Logical Memory II delayed recall score ≥ 6 and ≤ 18 .&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of dementia as assessed by the investigator&#xD;
&#xD;
          -  Use of omega-3 preparations in the last 3 months&#xD;
&#xD;
          -  &gt; 200 mg/day of DHA consumption using a validated questionnaire&#xD;
&#xD;
          -  Use of donepezil, rivastigmine, galantamine and/or memantine&#xD;
&#xD;
          -  Alcohol or drug abuse&#xD;
&#xD;
          -  A concomitant serious disease such as active cancer treatment or HIV.&#xD;
&#xD;
          -  Participation in a clinical trial in the last 30 days&#xD;
&#xD;
          -  Use of anticoagulants such as Plavix or Coumadin or the newer generation blood&#xD;
             thinners.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hussein Yassine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USC Keck School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Yassine HN, Braskie MN, Mack WJ, Castor KJ, Fonteh AN, Schneider LS, Harrington MG, Chui HC. Association of Docosahexaenoic Acid Supplementation With Alzheimer Disease Stage in Apolipoprotein E ε4 Carriers: A Review. JAMA Neurol. 2017 Mar 1;74(3):339-347. doi: 10.1001/jamaneurol.2016.4899. Review.</citation>
    <PMID>28114437</PMID>
  </reference>
  <verification_date>June 2022</verification_date>
  <study_first_submitted>July 11, 2018</study_first_submitted>
  <study_first_submitted_qc>July 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2018</study_first_posted>
  <last_update_submitted>June 2, 2022</last_update_submitted>
  <last_update_submitted_qc>June 2, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern California</investigator_affiliation>
    <investigator_full_name>Hussein Yassine</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <keyword>Docosahexaenoic Acids</keyword>
  <keyword>Apolipoprotein E4</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>available by request to study principal investigator and after approval by study committee.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>within 1 year after study publication</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

